首页> 美国卫生研究院文献>PPAR Research >Differential Roles of Peroxisome Proliferator-Activated Receptor-α and Receptor-γ on Renal Crystal Formation in Hyperoxaluric Rodents
【2h】

Differential Roles of Peroxisome Proliferator-Activated Receptor-α and Receptor-γ on Renal Crystal Formation in Hyperoxaluric Rodents

机译:过氧化物酶体增殖物激活的受体-α和受体-γ对高草酸啮齿动物肾脏晶体形成的不同作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Peroxisome proliferator-activated receptors (PPARs) and related inflammatory and oxidative molecule expression were investigated in a hyperoxaluric rodent model to evaluate the in vivo efficacy of PPAR agonists in preventing renal crystal formation. PPAR expression was examined in a mouse hyperoxaluria kidney stone model induced by daily intra-abdominal glyoxylate injection. Therapeutic effects of the PPARα agonist fenofibrate and PPARγ agonist pioglitazone were also assessed in a 1% ethylene glycol-induced rat model of hyperoxaluria. Crystal formation, inflammation, cell injury, apoptosis, and oxidative stress were compared to those of vehicle-treated controls. Quantitative reverse transcription-polymerase chain reaction revealed that PPARα and PPARγ expression decrease and increase, respectively, during crystal formation in hyperoxaluric kidneys. In addition, PPARα localized to the cytoplasm of both proximal and distal tubular cells, whereas PPARγ accumulated in the nucleus of proximal tubular cells. Furthermore, renal crystal formation was significantly less prevalent in pioglitazone-treated rats but higher in the fenofibrate-treated and fenofibrate/pioglitazone-cotreated groups compared to controls, thus indicating that pioglitazone, but not fenofibrate, markedly decreased cell inflammation, oxidative stress, and apoptosis. Collectively, the results demonstrated that PPARγ suppressed renal crystal formation via its antioxidative and anti-inflammatory effects; however, the renotoxicity of PPARα may elicit the opposite effect.
机译:在高草酸啮齿动物模型中研究了过氧化物酶体增殖物激活受体(PPARs)和相关的炎症和氧化分子表达,以评估PPAR激动剂在预防肾晶体形成中的体内功效。在每天腹腔内乙醛酸注射诱导的小鼠高草酸尿症肾结石模型中检查了PPAR表达。在1%乙二醇诱导的高草酸尿大鼠模型中也评估了PPARα激动剂非诺贝特和PPARγ激动剂吡格列酮的治疗作用。将晶体形成,炎症,细胞损伤,细胞凋亡和氧化应激与载体处理的对照进行比较。定量逆转录-聚合酶链反应显示,在高草酸尿性肾脏的晶体形成过程中,PPARα和PPARγ的表达分别减少和增加。另外,PPARα定位于近端和远端小管细胞的细胞质,而PPARγ聚集在近端小管细胞的核中。此外,与吡格列酮治疗组相比,吡格列酮治疗组大鼠的肾脏晶体形成显着减少,但非诺贝特治疗组和非诺贝特/吡格列酮治疗组的肾结晶形成率更高,因此表明吡格列酮而非非诺贝特显着降低了细胞炎症,氧化应激和细胞凋亡。总的来说,结果表明PPARγ通过其抗氧化和抗炎作用抑制了肾晶体的形成。然而,PPARα的肾毒性可能引起相反的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号